Human IL-13 R alpha 2 Antibody

Catalog # Availability Size / Price Qty
AF146
AF146-SP
Detection of Human IL‑13 R alpha 2 by Western Blot.
18 Images
Product Details
Citations (25)
FAQs
Supplemental Products
Reviews

Human IL-13 R alpha 2 Antibody Summary

Species Reactivity
Human
Specificity
Detects human IL-13 R alpha 2 in direct ELISAs and Western blots. In direct ELISAs, approximately 5% cross-reactivity with recombinant mouse IL-13 R alpha 2 is observed and less than 1% cross-reactivity with recombinant human IL-13 R alpha 1 is observed.
Source
Polyclonal Goat IgG
Purification
Antigen Affinity-purified
Immunogen
Mouse myeloma cell line NS0-derived recombinant human IL‑13 R alpha 2
Cys22-Leu342
Accession # Q14627
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Western Blot
0.2 µg/mL
See below
Simple Western
10 µg/mL
See below
Flow Cytometry
2.5 µg/106 cells
A375 human melanoma cell line
Immunohistochemistry
5-15 µg/mL
See below
Blockade of Receptor-ligand Interaction
In a functional ELISA, 2-6 µg/mL of this antibody will block 50% of the binding of 100 ng/mL of Recombinant Human IL-13 (Catalog # 213‑ILB) to immobilized Recombinant Human IL-13 R alpha 2 Fc Chimera (Catalog # 614-INS) coated at 4 µg/mL (100 µL/well). At 40 μg/mL, this antibody will block >90% of the binding.
 
CyTOF-ready
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
 

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Western Blot Detection of Human IL-13 Ra2 antibody by Western Blot. View Larger

Detection of Human IL‑13 R alpha 2 by Western Blot. Western blot shows lysates of human placenta tissue and human testis tissue. PVDF membrane was probed with 0.2 µg/mL of Goat Anti-Human IL-13 Ra2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF146) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for IL-13 Ra2 at approximately 50-55 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Immunohistochemistry IL-13 Ra2 antibody in Human Prostate Cancer Tissue by Immunohistochemistry (IHC-P). View Larger

IL-13 R alpha 2 in Human Prostate Cancer Tissue. IL-13 Ra2 was detected in immersion fixed paraffin-embedded sections of human prostate cancer tissue using Goat Anti-Human IL-13 Ra2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF146) at 5 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to glandular epithelial cells. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Simple Western Detection of Human IL-13 Ra2 antibody by Simple Western<sup>TM</sup>. View Larger

Detection of Human IL‑13 R alpha 2 by Simple WesternTM. Simple Western lane view shows lysates of human placenta tissue and human testis tissue, loaded at 0.2 mg/mL. A specific band was detected for IL-13 Ra2 at approximately 59 kDa (as indicated) using 10 µg/mL of Goat Anti-Human IL-13 Ra2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF146) followed by 1:50 dilution of HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

Flow Cytometry Detection of Human IL-13R alpha 2 by Flow Cytometry View Larger

Detection of Human IL-13R alpha 2 by Flow Cytometry Evaluation of additional commercially available B-D13 antibodies.(A) PBT008 cells that had been cultured overnight in media alone (black histogram) versus cytokine (TNF; red histogram) conditions, (B) Parental 293T cells or 293T cells engineered to express either VCAM-1 or IL13R alpha 2, and (C) U251T cells were stained with VCAM-1-PE, AF146 or various B-D13 reagents – two lots of PE-conjugated B-D13 antibody (B-D13-PE; Cell Sciences) and two to three unconjugated B-D13 antibodies (B-D13-unc) purchased from either Cell Sciences (Cell Sci), Abcam or Santa Cruz as indicated. (B, C) Black histograms represent staining with istoype control antibody or SA-PE alone. Image collected and cropped by CiteAb from the following open publication (https://dx.plos.org/10.1371/journal.pone.0095123), licensed under a CC-BY license. Not internally tested by R&D Systems.

Western Blot Detection of Human IL-13R alpha 2 by Western Blot View Larger

Detection of Human IL-13R alpha 2 by Western Blot Deletion of the cytoplasmic domain of IL-13R alpha 2 resulted in a loss of physical interaction with EGFRvIII and enhanced proliferation is abolished. a Whole-cell lysates prepared from stable cell line Gli36.IL-13R alpha 2/EGFRvIII cells were used for immunoprecipitation with anti-IL-13R alpha 2 antibody, then immunoprobed with an anti-EGFR antibody. IgG served as control while unprecipitated extracts serve as input. b Similar cell lysates were reverse immunoprecipitated with anti-EGFR antibody, then immunoprobed with an anti-IL13R alpha 2antibody. Lysates from Gli36.EGFRvIII served as additional control c Gli36.IL-13R alpha 2/EGFRvIII cell lysates were immunoprecipitated with anti-EGFR antibody, then immunoprobed with anti-Grb antibody. To further examine the domains of interaction, IL-13R alpha 2 and EGFR mutants were used. Gli36.EGFRvIII cells were first transfected with pIRESneo2 (Vector), IL-13R alpha 2 full length (Wild-type) and IL-13R alpha 2 Cyt tail deleted constructs (Mutant) and then analyzed by d cell proliferation assay at the indicated time points, f co-immunoprecipitation, and h PLA assays. Findings were validated using Gli36.IL-13R alpha 2 cells transiently transfected with vector (CTRL), full length/wild-type EGFRvIII, DK, and DY3 mutants. e proliferation outputs, g co-immunoprecipitation, i and PLA assay were performed. j represent the corresponding positive and negative controls. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/29203859), licensed under a CC-BY license. Not internally tested by R&D Systems.

Western Blot Detection of Human IL-13R alpha 2 by Western Blot View Larger

Detection of Human IL-13R alpha 2 by Western Blot GBM patients co-expressing EGFR and IL-13R alpha 2 correlate to poor survival where the overexpression of IL-13R alpha 2 alone leads to enhance cell migration but not proliferation. Kaplan−Meier survival analysis of a all gliomas patients; b GBM patients from REMBRANDT database from National Cancer Institute (USA). Patients overexpressing EGFR mRNA by 2-fold (blue) with high (red), intermediate (yellow) and low (green) levels of IL-13R alpha 2 expression were shown. The log-rank p-values were indicated. c Kaplan−Meier survival plots for patients expressing high YKL-40 mRNA levels TCGA. High IL-13R alpha 2 expression group (red) and low IL-13R alpha 2 expression group (blue) were determined by aggregating all patients whose z-score normalized expression was above or below 0, respectively (Log-rank test p-value = 0.0374). Immunoblotting analysis showed the expression of EGFR and IL-13R alpha 2 protein levels were determined from d a panel of 10 patient-derived GBM e and the isogenic cell lines generated from Gli36 glioma cells. Pan-actin or beta tubulin served as internal loading controls. f Cell proliferation and g Cell cycle analysis were performed with Gli36 and Gli36.IL-13R alpha 2 cells h Soft agar colony formation assay was performed, Gli36.EGFRvIII was used as a positive control. i In vitro migration and j invasion assays were determined in Gli36 and Gli36.IL-13R alpha 2 cells. All data are represented as mean ± SEM, unpaired t-test **p < 0.01; ***p < 0.001; NS not significant. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/29203859), licensed under a CC-BY license. Not internally tested by R&D Systems.

Flow Cytometry Detection of Human IL-13R alpha 2 by Flow Cytometry View Larger

Detection of Human IL-13R alpha 2 by Flow Cytometry The cytokine-induced cell surface antigen recognized by B-D13-PE does not bind IL-13.(A) D283 cells engineered to express IL13R alpha 2 (D283- IL13R alpha 2) (blue histograms) and D283 parental (black histograms) cells were evaluated by flow cytometry for expression of constitutive IL13R alpha 2 using the IL13R alpha 2-specific antibody AF146, and biotinylated recombinant human IL-13 (IL13-bio) followed by PE-conjugated strepavidin (SA-PE). Data are representative of 2 separate experiments. (B) U251T (grown in the absence of cytokines) were evaluated by flow cytometry for constitutive IL13R alpha 2 expression using AF146, and for binding to IL13-bio/SA-PE in the presence and absence of 10-fold molar excess of recombinant human IL-4 or IL-13. Black histograms represent staining with istoype control antibody or SA-PE alone. Data are representative of 2 separate experiments. (C) THP-1 and PBT008 grown in media alone (black histograms) or induced overnight with TNF and IL-4 (red histograms) were analyzed by flow cytometry for expression of constitutive IL13R alpha 2 (AF146), for expression of the induced antigen (B-D13-PE), and for binding to IL13-bio/SA-PE. Data are representative of 3 separate experiments. (D) IL13-zetakine+ CD8+ CTL recognize and kill U251T glioma targets expressing constitutive IL13R alpha 2 (AF146-positive), but not cytokine-induced PBT003 cells (B-D13-positive). Percentage specific lysis (mean ± S.D.) of triplicate wells is depicted. *, p≤0.0002 using an unpaired Student's t-test to compare U251T vs. PBT003-4 targets. #, p>0.05 using an unpaired Student's t-test to compare PBT003-4 targets with and without overnight cytokine stimulation. Data are representative of at least 2 separate experiments. Image collected and cropped by CiteAb from the following open publication (https://dx.plos.org/10.1371/journal.pone.0095123), licensed under a CC-BY license. Not internally tested by R&D Systems.

Flow Cytometry Detection of Human IL-13R alpha 2 by Flow Cytometry View Larger

Detection of Human IL-13R alpha 2 by Flow Cytometry Evaluation of additional commercially available B-D13 antibodies.(A) PBT008 cells that had been cultured overnight in media alone (black histogram) versus cytokine (TNF; red histogram) conditions, (B) Parental 293T cells or 293T cells engineered to express either VCAM-1 or IL13R alpha 2, and (C) U251T cells were stained with VCAM-1-PE, AF146 or various B-D13 reagents – two lots of PE-conjugated B-D13 antibody (B-D13-PE; Cell Sciences) and two to three unconjugated B-D13 antibodies (B-D13-unc) purchased from either Cell Sciences (Cell Sci), Abcam or Santa Cruz as indicated. (B, C) Black histograms represent staining with istoype control antibody or SA-PE alone. Image collected and cropped by CiteAb from the following open publication (https://dx.plos.org/10.1371/journal.pone.0095123), licensed under a CC-BY license. Not internally tested by R&D Systems.

Flow Cytometry Detection of Mouse IL-13R alpha 2 by Flow Cytometry View Larger

Detection of Mouse IL-13R alpha 2 by Flow Cytometry Differential recognition of constitutively-expressed versus cytokine-induced IL13R alpha 2 by commercially available anti-IL13R alpha 2 antibodies.Flow cytometric analysis of monocytic line THP-1 and various glioma lines with (A) B-D13-PE (Cell Sciences) or (B) AF146 (R&D Systems) reagents for media alone (black histogram) and cytokine (TNF/IL-4 or TNF/IL-13 overnight; red histogram) conditions. Isotype (iso-PE) and mouse anti-goat-FITC controls are shown as grey histograms. Percent positive and relative fluorescent index (RFI) of MFI cytokine/MFI media is reported for each histogram. (C) Flow cytometric detection of IL13R alpha 2 for D283 cells engineered to express IL13R alpha 2 (D283-IL13R alpha 2; blue histogram) and D283 parental (black histogram) stained with AF146 or B-D13-PE antibodies. All data are representative of more than three experiments each. Image collected and cropped by CiteAb from the following open publication (https://dx.plos.org/10.1371/journal.pone.0095123), licensed under a CC-BY license. Not internally tested by R&D Systems.

Western Blot Detection of Human IL-13R alpha 2 by Western Blot View Larger

Detection of Human IL-13R alpha 2 by Western Blot Deletion of the cytoplasmic domain of IL-13R alpha 2 resulted in a loss of physical interaction with EGFRvIII and enhanced proliferation is abolished. a Whole-cell lysates prepared from stable cell line Gli36.IL-13R alpha 2/EGFRvIII cells were used for immunoprecipitation with anti-IL-13R alpha 2 antibody, then immunoprobed with an anti-EGFR antibody. IgG served as control while unprecipitated extracts serve as input. b Similar cell lysates were reverse immunoprecipitated with anti-EGFR antibody, then immunoprobed with an anti-IL13R alpha 2antibody. Lysates from Gli36.EGFRvIII served as additional control c Gli36.IL-13R alpha 2/EGFRvIII cell lysates were immunoprecipitated with anti-EGFR antibody, then immunoprobed with anti-Grb antibody. To further examine the domains of interaction, IL-13R alpha 2 and EGFR mutants were used. Gli36.EGFRvIII cells were first transfected with pIRESneo2 (Vector), IL-13R alpha 2 full length (Wild-type) and IL-13R alpha 2 Cyt tail deleted constructs (Mutant) and then analyzed by d cell proliferation assay at the indicated time points, f co-immunoprecipitation, and h PLA assays. Findings were validated using Gli36.IL-13R alpha 2 cells transiently transfected with vector (CTRL), full length/wild-type EGFRvIII, DK, and DY3 mutants. e proliferation outputs, g co-immunoprecipitation, i and PLA assay were performed. j represent the corresponding positive and negative controls. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/29203859), licensed under a CC-BY license. Not internally tested by R&D Systems.

Western Blot Detection of Human IL-13R alpha 2 by Western Blot View Larger

Detection of Human IL-13R alpha 2 by Western Blot IL-13R alpha 2 mediate greater tumorigenic potential with EGFRvIII, and not WT EGFR. a Tumor volume b and tumor weight of tetracycline regulatable U251 gliomas (U251-E6 and U251-E18 was examined in vivo. Bars depict the mean values and error bars represent 95% confidence intervals. P-values were calculated using ANOVA with Tukey’s multiple comparison test *p < 0.05; **p < 0.01; ***p < 0.001. Photomicrographs of represented collected tumors are shown. c Immunoblot analysis of proteins from U251-E6 and -E18 tumor lysates in the presence or absence of tetracycline with the indicated antibodies. One representative tumor under each of the uninduced and induced conditions was shown. U251MG whole-cell lysate served as positive control for IL-13R alpha 2. d Kaplan−Meier survival curves of mice bearing U251-E6 and U251-18 tumors **p < 0.0039. Kaplan−Meier survival plots for patients expressing e high EGFR mRNA levels (excluding EGFRvIII) or f high EGFRvIII mRNA levels from TCGA database. High IL-13R alpha 2 expression (red) and low IL-13R alpha 2 expression (blue) were determined by aggregating all patients whose z-score normalized expression was above or below 0, respectively. g Schematic model showing signal transduction pathway co-induced by IL-13R alpha 2 and EGFRvIII. Overexpression of IL-13R alpha 2 in human gliomas increases cell migration and invasion through the activation of MMP-2, vimentin. Amplification of EGFRvIII promotes the co-interaction of both receptors mediating an increase in tyrosine kinase activities and a preferential activation of RAS-MEK-ERK and STAT3 pathways leading to aberrant cellular proliferation. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/29203859), licensed under a CC-BY license. Not internally tested by R&D Systems.

Flow Cytometry Detection of Mouse IL-13R alpha 2 by Flow Cytometry View Larger

Detection of Mouse IL-13R alpha 2 by Flow Cytometry Cytokine induction of B-D13 antigen is dependent on mRNA transcription and translation.(A) IL13R alpha 2 mRNA levels quantified by qPCR for U251T, PBT003-4, PBT008, and THP-1 cells after overnight culture in media, TNF/IL-4, or TNF/IL-13. mRNA levels were normalized to housekeeping genes (ACTB, UBC, GAPDH and RPLP0). (B, C) B-D13-PE immunoreactivity of PBT008 and THP-1 cells treated with increasing concentrations of (B) transcription blocker Actinomycin D (ActD) (0, 0.06, 0.1, 0.3 µg/ml) or (C) translation blocker Cycloheximide (CHX) (0, 2.5, 5, 10 µg/ml), then either cultured in media alone (black histograms) or stimulated with TNF/IL-4 (red histograms) for 5 hours. All data are representative of 2 separate experiments. Image collected and cropped by CiteAb from the following open publication (https://dx.plos.org/10.1371/journal.pone.0095123), licensed under a CC-BY license. Not internally tested by R&D Systems.

Flow Cytometry Detection of Human IL-13R alpha 2 by Flow Cytometry View Larger

Detection of Human IL-13R alpha 2 by Flow Cytometry The cytokine-induced cell surface antigen recognized by B-D13-PE does not bind IL-13.(A) D283 cells engineered to express IL13R alpha 2 (D283- IL13R alpha 2) (blue histograms) and D283 parental (black histograms) cells were evaluated by flow cytometry for expression of constitutive IL13R alpha 2 using the IL13R alpha 2-specific antibody AF146, and biotinylated recombinant human IL-13 (IL13-bio) followed by PE-conjugated strepavidin (SA-PE). Data are representative of 2 separate experiments. (B) U251T (grown in the absence of cytokines) were evaluated by flow cytometry for constitutive IL13R alpha 2 expression using AF146, and for binding to IL13-bio/SA-PE in the presence and absence of 10-fold molar excess of recombinant human IL-4 or IL-13. Black histograms represent staining with istoype control antibody or SA-PE alone. Data are representative of 2 separate experiments. (C) THP-1 and PBT008 grown in media alone (black histograms) or induced overnight with TNF and IL-4 (red histograms) were analyzed by flow cytometry for expression of constitutive IL13R alpha 2 (AF146), for expression of the induced antigen (B-D13-PE), and for binding to IL13-bio/SA-PE. Data are representative of 3 separate experiments. (D) IL13-zetakine+ CD8+ CTL recognize and kill U251T glioma targets expressing constitutive IL13R alpha 2 (AF146-positive), but not cytokine-induced PBT003 cells (B-D13-positive). Percentage specific lysis (mean ± S.D.) of triplicate wells is depicted. *, p≤0.0002 using an unpaired Student's t-test to compare U251T vs. PBT003-4 targets. #, p>0.05 using an unpaired Student's t-test to compare PBT003-4 targets with and without overnight cytokine stimulation. Data are representative of at least 2 separate experiments. Image collected and cropped by CiteAb from the following open publication (https://dx.plos.org/10.1371/journal.pone.0095123), licensed under a CC-BY license. Not internally tested by R&D Systems.

Flow Cytometry Detection of Human IL-13R alpha 2 by Flow Cytometry View Larger

Detection of Human IL-13R alpha 2 by Flow Cytometry The cytokine-induced cell surface antigen recognized by B-D13-PE does not bind IL-13.(A) D283 cells engineered to express IL13R alpha 2 (D283- IL13R alpha 2) (blue histograms) and D283 parental (black histograms) cells were evaluated by flow cytometry for expression of constitutive IL13R alpha 2 using the IL13R alpha 2-specific antibody AF146, and biotinylated recombinant human IL-13 (IL13-bio) followed by PE-conjugated strepavidin (SA-PE). Data are representative of 2 separate experiments. (B) U251T (grown in the absence of cytokines) were evaluated by flow cytometry for constitutive IL13R alpha 2 expression using AF146, and for binding to IL13-bio/SA-PE in the presence and absence of 10-fold molar excess of recombinant human IL-4 or IL-13. Black histograms represent staining with istoype control antibody or SA-PE alone. Data are representative of 2 separate experiments. (C) THP-1 and PBT008 grown in media alone (black histograms) or induced overnight with TNF and IL-4 (red histograms) were analyzed by flow cytometry for expression of constitutive IL13R alpha 2 (AF146), for expression of the induced antigen (B-D13-PE), and for binding to IL13-bio/SA-PE. Data are representative of 3 separate experiments. (D) IL13-zetakine+ CD8+ CTL recognize and kill U251T glioma targets expressing constitutive IL13R alpha 2 (AF146-positive), but not cytokine-induced PBT003 cells (B-D13-positive). Percentage specific lysis (mean ± S.D.) of triplicate wells is depicted. *, p≤0.0002 using an unpaired Student's t-test to compare U251T vs. PBT003-4 targets. #, p>0.05 using an unpaired Student's t-test to compare PBT003-4 targets with and without overnight cytokine stimulation. Data are representative of at least 2 separate experiments. Image collected and cropped by CiteAb from the following open publication (https://dx.plos.org/10.1371/journal.pone.0095123), licensed under a CC-BY license. Not internally tested by R&D Systems.

Western Blot Detection of Human IL-13R alpha 2 by Western Blot View Larger

Detection of Human IL-13R alpha 2 by Western Blot Enhanced cellular proliferation mediated by IL-13R alpha 2 is specific to EGFRvIII, and not WT EGFR. a U251-E6 or c U251-E18 cells were treated with or without tetracycline (Tet). At indicated time points, immunoblot analysis was carried out. Gli36, Gli36.EGFRvIII cell lysates were included as negative or positive controls for EGFRvIII, respectively. Growth kinetics of b U251-E6 and d U251-E18 was determined by CCK-8 assay. Percent cell viability was normalized to day 1 (without induction). All data are represented as mean ± SEM. Unpaired t-test ***p < 0.001, NS. not significant. e Co-immunoprecipitation was performed in stable cell lines Gli36.IL-13R alpha 2/wtEGFR as well as U251MG-E6 (i.e. wtEGFR) cells at 48 h post tetracycline induction with the indicated antibodies. Gli36.IL-13R alpha 2/EGFRvIII served as positive controls. f The interaction between endogenous wtEGFR and IL-13R alpha 2 was shown in primary wtEGFR-positive GBM patient tumor derived from Mayo clinic, and IgG served as positive and negative controls respectively. Knockdown of IL-13R alpha 2 in cell line or patient-derived GBM samples expressing g wtEGFR or h EGFRvIII. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/29203859), licensed under a CC-BY license. Not internally tested by R&D Systems.

Flow Cytometry Detection of Human IL-13R alpha 2 by Flow Cytometry View Larger

Detection of Human IL-13R alpha 2 by Flow Cytometry B-D13 reagent appears to contain two distinct monoclonal antibodies.Soluble receptor competition study evaluating the specificity of IL13R alpha 2 and VCAM-1 recognition by the B-D13-unc antibodies (Cell Sciences and Santa Cruz) using (A) PBT008 cells cultured overnight in media alone (black histogram) versus cytokine (TNF; blue histogram); or (B) IL13R alpha 2-expressing U251T cells (blue histogram). Cells were stained with the indicated antibody that was pre-incubated with soluble recombinant human IL13R alpha -Fc (purple histograms) or VCAM-1-Fc (green histograms). Relative fluorescence index (RFI) compared to staining without the soluble competitors (i.e., the control/blue histograms) are indicated in each histogram. (C) Unconjugated B-D13 antibodies from Cell Sciences (top) and Abcam (bottom) were reduced and analyzed by LC/MS. Shown is the spectra of the deconvoluted protein masses depicting two distinct mass species for both the heavy and light chains. (D) Extracted ion chromatograms (EIC) for the two light chain species, of the Cell Sciences B-D13-unc reagent from (C). Image collected and cropped by CiteAb from the following open publication (https://dx.plos.org/10.1371/journal.pone.0095123), licensed under a CC-BY license. Not internally tested by R&D Systems.

Western Blot Detection of Human IL-13R alpha 2 by Western Blot View Larger

Detection of Human IL-13R alpha 2 by Western Blot GBM patients co-expressing EGFR and IL-13R alpha 2 correlate to poor survival where the overexpression of IL-13R alpha 2 alone leads to enhance cell migration but not proliferation. Kaplan−Meier survival analysis of a all gliomas patients; b GBM patients from REMBRANDT database from National Cancer Institute (USA). Patients overexpressing EGFR mRNA by 2-fold (blue) with high (red), intermediate (yellow) and low (green) levels of IL-13R alpha 2 expression were shown. The log-rank p-values were indicated. c Kaplan−Meier survival plots for patients expressing high YKL-40 mRNA levels TCGA. High IL-13R alpha 2 expression group (red) and low IL-13R alpha 2 expression group (blue) were determined by aggregating all patients whose z-score normalized expression was above or below 0, respectively (Log-rank test p-value = 0.0374). Immunoblotting analysis showed the expression of EGFR and IL-13R alpha 2 protein levels were determined from d a panel of 10 patient-derived GBM e and the isogenic cell lines generated from Gli36 glioma cells. Pan-actin or beta tubulin served as internal loading controls. f Cell proliferation and g Cell cycle analysis were performed with Gli36 and Gli36.IL-13R alpha 2 cells h Soft agar colony formation assay was performed, Gli36.EGFRvIII was used as a positive control. i In vitro migration and j invasion assays were determined in Gli36 and Gli36.IL-13R alpha 2 cells. All data are represented as mean ± SEM, unpaired t-test **p < 0.01; ***p < 0.001; NS not significant. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/29203859), licensed under a CC-BY license. Not internally tested by R&D Systems.

Flow Cytometry Detection of Human IL-13R alpha 2 by Flow Cytometry View Larger

Detection of Human IL-13R alpha 2 by Flow Cytometry The cytokine-induced cell surface antigen recognized by B-D13-PE does not bind IL-13.(A) D283 cells engineered to express IL13R alpha 2 (D283- IL13R alpha 2) (blue histograms) and D283 parental (black histograms) cells were evaluated by flow cytometry for expression of constitutive IL13R alpha 2 using the IL13R alpha 2-specific antibody AF146, and biotinylated recombinant human IL-13 (IL13-bio) followed by PE-conjugated strepavidin (SA-PE). Data are representative of 2 separate experiments. (B) U251T (grown in the absence of cytokines) were evaluated by flow cytometry for constitutive IL13R alpha 2 expression using AF146, and for binding to IL13-bio/SA-PE in the presence and absence of 10-fold molar excess of recombinant human IL-4 or IL-13. Black histograms represent staining with istoype control antibody or SA-PE alone. Data are representative of 2 separate experiments. (C) THP-1 and PBT008 grown in media alone (black histograms) or induced overnight with TNF and IL-4 (red histograms) were analyzed by flow cytometry for expression of constitutive IL13R alpha 2 (AF146), for expression of the induced antigen (B-D13-PE), and for binding to IL13-bio/SA-PE. Data are representative of 3 separate experiments. (D) IL13-zetakine+ CD8+ CTL recognize and kill U251T glioma targets expressing constitutive IL13R alpha 2 (AF146-positive), but not cytokine-induced PBT003 cells (B-D13-positive). Percentage specific lysis (mean ± S.D.) of triplicate wells is depicted. *, p≤0.0002 using an unpaired Student's t-test to compare U251T vs. PBT003-4 targets. #, p>0.05 using an unpaired Student's t-test to compare PBT003-4 targets with and without overnight cytokine stimulation. Data are representative of at least 2 separate experiments. Image collected and cropped by CiteAb from the following open publication (https://dx.plos.org/10.1371/journal.pone.0095123), licensed under a CC-BY license. Not internally tested by R&D Systems.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS.
Reconstitution Buffer Available
Reconstitution Buffer 1 (PBS)
Catalog #
Availability
Size / Price
Qty
RB01
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IL-13 R alpha 2

Two type1 membrane proteins belonging to the hemopoietin receptor family have been cloned and shown to bind IL-13 with differing affinities. The lower affinity IL-13 binding protein, previously designated IL-13 R alpha, IL-13 R alpha l or NR4, is now referred to as IL-13 R alpha 1. The high affinity IL-13 binding protein, previously also designated IL-13 R or IL-13 R alpha l, is now referred to as IL-13 R alpha 2. Human IL-13 R alpha 2 was originally cloned from the Caki-1 human renal carcinoma cell line. The IL-13 R alpha 2 cDNA encodes a 380 amino acid (aa) residue precursor protein with a putative 26 aa residue signal peptide, a 317 residue extracellular domain, a 20 aa residue transmembrane region and a 17 aa residue cytoplasmic tail. Human and mouse IL‑13 R alpha 2 share 59% aa sequence identity. The extracellular domain of IL-13 R alpha 2 is also closely related to that of IL-13 R alpha 1. However, the 17 aa residue cytoplasmic domain of IL-13 R alpha 2 is much shorter than that of IL-13 R alpha 1, suggesting that the two receptors are functionally distinct. IL-13 R alpha 1 has been shown to combine with the IL-4 R to form a high-affinity receptor complex capable of transducing an IL‑13‑dependent proliferative signal. The role of IL-13 R alpha 2 in IL-13 signaling remains to be elucidated. The amino-terminal 27 aa residues of the human and mouse IL‑13 R alpha 2 are nearly identical to that of a soluble mouse IL-13 binding protein purified from mouse serum and urine.

References
  1. Caput, D. et al. (1996) J. Biol. Chem. 271:16921.
  2. Donaldson, D.D. et al. (1998) J. Immunol. 161:2317.
  3. Aman, M.J. et al. (1996) J. Biol. Chem. 271:29265.
  4. Hilton, D.J. et al. (1996) Proc. Natl. Acad. Sci. USA 93:497.
  5. Zhang, J.G. et al. (1997) J. Biol. Chem. 272:9474.
  6.  
Long Name
Interleukin 13 Receptor alpha 2
Entrez Gene IDs
3598 (Human); 16165 (Mouse)
Alternate Names
cancer/testis antigen 19; CD213a2 antigen; CD213a2; CT19; IL-13 R alpha 2; IL-13 receptor subunit alpha-2; IL13BP; IL13R alpha 2; IL-13R subunit alpha-2; IL13R; IL-13R; IL13RA2; IL-13Ra2; IL-13R-alpha-2; interleukin 13 binding protein; interleukin 13 receptor alpha 2 chain; interleukin 13 receptor, alpha 2; interleukin-13 receptor subunit alpha-2; Interleukin-13-binding protein

Product Datasheets

You must select a language.

x

Citations for Human IL-13 R alpha 2 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

25 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. The IL-4/IL-13 signaling axis promotes prostatic fibrosis
    Authors: Q D'Arcy, M Gharaee-Ke, A Zhilin-Rot, JA Macoska
    PLoS ONE, 2022-10-06;17(10):e0275064.
    Species: Human
    Sample Types: Cell Lysates, Whole Tissue
    Applications: IHC, Western Blot
  2. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma
    Authors: LK Donovan, A Delaidelli, SK Joseph, K Bielamowic, K Fousek, BL Holgado, A Manno, D Srikanthan, AZ Gad, R Van Ommere, D Przelicki, C Richman, V Ramaswamy, C Daniels, JG Pallota, T Douglas, ACM Joynt, J Haapasalo, C Nor, MC Vladoiu, CM Kuzan-Fisc, L Garzia, SC Mack, S Varadharaj, ML Baker, L Hendrikse, M Ly, K Kharas, P Balin, X Wu, L Qin, N Huang, AG Stucklin, AS Morrissy, FMG Cavalli, B Luu, R Suarez, P De Antonel, A Michealraj, A Rastan, M Hegde, M Komosa, O Sirbu, SA Kumar, Z Abdullaev, CC Faria, S Yip, J Hukin, U Tabori, C Hawkins, K Aldape, M Daugaard, JM Maris, PH Sorensen, N Ahmed, MD Taylor
    Nat. Med., 2020-04-27;26(5):720-731.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  3. Identification of a novel role of IL-13R?2 in human Glioblastoma multiforme: interleukin-13 mediates signal transduction through AP-1 pathway
    Authors: R Bhardwaj, A Suzuki, P Leland, BH Joshi, RK Puri
    J Transl Med, 2018-12-20;16(1):369.
    Species: Human
    Sample Types: Whole Cells, Whole Tissue
    Applications: ICC, IHC
  4. IL-13 receptors as possible therapeutic targets in diffuse intrinsic pontine glioma
    Authors: NE Berlow, MN Svalina, MJ Quist, TP Settelmeye, V Zherebitsk, M Kogiso, L Qi, Y Du, CE Hawkins, E Hulleman, XN Li, SH Gultekin, C Keller
    PLoS ONE, 2018-04-05;13(4):e0193565.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  5. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma.
    Authors: Bielamowicz K, Fousek K, Byrd T, Samaha H, Mukherjee M, Aware N, Wu M, Orange J, Sumazin P, Man T, Joseph S, Hegde M, Ahmed N
    Neuro Oncol, 2018-03-27;20(4):506-518.
    Species: Xenograft
    Sample Types: Whole Tissue
  6. Optimization of IL13R?2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma
    Authors: CE Brown, B Aguilar, R Starr, X Yang, WC Chang, L Weng, B Chang, A Sarkissian, A Brito, JF Sanchez, JR Ostberg, M D'Apuzzo, B Badie, ME Barish, SJ Forman
    Mol. Ther., 2017-10-05;26(1):31-44.
    Species: Human
    Sample Types: Xenograft
    Applications: Flow Cytometry
  7. IL-4 primes the dynamics of breast cancer progression via DUSP4 inhibition
    Authors: M Gaggianesi, A Turdo, A Chinnici, E Lipari, T Apuzzo, A Benfante, I Sperduti, S Di Franco, S Meraviglia, E Lo Presti, F Dieli, V Caputo, G Militello, S Vieni, G Stassi, M Todaro
    Cancer Res., 2017-04-11;0(0):.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  8. Cigarette smoke extracts induce overexpression of the proto-oncogenic gene interleukin-13 receptor ?2 through activation of the PKA-CREB signaling pathway to trigger malignant transformation of lung vascular endothelial cells and angiogenesis
    Authors: Mei Meng
    Cell. Signal, 2016-12-13;0(0):.
  9. IL-13R?2 uses TMEM219 in chitinase 3-like-1-induced signalling and effector responses
    Nat Commun, 2016-09-15;7(0):12752.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Immunoprecipitation
  10. Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape.
    Authors: Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai S, Wakefield A, Fousek K, Bielamowicz K, Chow K, Brawley V, Byrd T, Krebs S, Gottschalk S, Wels W, Baker M, Dotti G, Mamonkin M, Brenner M, Orange J, Ahmed N
    J Clin Invest, 2016-07-18;126(8):3036-52.
    Species: Human
    Sample Types: Whole Cells, Whole Tissue
    Applications: CAR-T (Flow Cytometry), CAR-T (IHC-P)
  11. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
    Authors: Shibasaki N, Yamasaki T, Kanno T, Arakaki R, Sakamoto H, Utsunomiya N, Inoue T, Tsuruyama T, Nakamura E, Ogawa O, Kamba T
    PLoS ONE, 2015-06-26;10(6):e0130980.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  12. Bioactivity and Safety of IL13Ralpha2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
    Authors: Brown C, Badie B, Barish M, Weng L, Ostberg J, Chang W, Naranjo A, Starr R, Wagner J, Wright C, Zhai Y, Bading J, Ressler J, Portnow J, D'Apuzzo M, Forman S, Jensen M
    Clin Cancer Res, 2015-06-09;21(18):4062-72.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  13. Expression of surfactant protein D in airways of asthmatics and interleukin-13 modulation of surfactant protein D in human models of airway epithelium.
    Authors: Xu J, Singhera G, Dorscheid D
    Respir Res, 2015-02-15;16(0):26.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  14. Cytokine induction of VCAM-1 but not IL13Ralpha2 on glioma cells: a tale of two antibodies.
    Authors: Mahadev V, Starr R, Wright S, Martinez C, Jensen M, Barish M, Forman S, Brown C
    PLoS ONE, 2014-05-02;9(5):e95123.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  15. IL-13Ralpha2 mediates PNR-induced migration and metastasis in ERalpha-negative breast cancer.
    Authors: Zhao Z, Wang L, Xu W
    Oncogene, 2014-04-21;34(12):1596-607.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  16. Absence of a role for interleukin-13 in inflammatory bowel disease.
    Authors: Biancheri P, Di Sabatino A, Ammoscato F, Facciotti F, Caprioli F, Curciarello R, Hoque S, Ghanbari A, Joe-Njoku I, Giuffrida P, Rovedatti L, Geginat J, Corazza G, MacDonald T
    Eur J Immunol, 2014-02-01;44(2):370-85.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  17. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.
    Authors: Hegde M, Corder A, Chow K, Mukherjee M, Ashoori A, Kew Y, Zhang Y, Baskin D, Merchant F, Brawley V, Byrd T, Krebs S, Wu M, Liu H, Heslop H, Gottschalk S, Yvon E, Ahmed N
    Mol Ther, 2013-08-13;21(11):2087-101.
    Species: Human
    Sample Types: Whole Tissue
    Applications: CAR-T (IHC-P)
  18. Matrix metalloproteinase 8 contributes to solubilization of IL-13 receptor alpha2 in vivo.
    Authors: Chen W, Tabata Y, Gibson AM, Daines MO, Warrier MR, Wills-Karp M, Hershey GK
    J. Allergy Clin. Immunol., 2008-08-09;122(3):625-32.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  19. Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity.
    Authors: Allen C, Paraskevakou G, Iankov I, Giannini C, Schroeder M, Sarkaria J, Schroeder M, Puri RK, Russell SJ, Galanis E
    Mol. Ther., 2008-07-29;16(9):1556-64.
    Species: Human
    Sample Types: Cell Lysates, Whole Cells
    Applications: ICC, Western Blot
  20. Development of an in vitro potency bioassay for therapeutic IL-13 antagonists: the A-549 cell bioassay.
    Authors: Miller R, Sadhukhan R, Wu C
    J. Immunol. Methods, 2008-03-07;334(1):134-41.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  21. Effect of IL-13 receptor alpha2 levels on the biological activity of IL-13 variant R110Q.
    Authors: Andrews AL, Bucchieri F, Arima K, Izuhara K, Holgate ST, Davies DE, Holloway JW
    J. Allergy Clin. Immunol., 2007-06-08;120(1):91-7.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  22. IL-13 receptor alpha 2: a regulator of IL-13 and IL-4 signal transduction in primary human fibroblasts.
    Authors: Andrews AL, Nasir T, Bucchieri F, Holloway JW, Holgate ST, Davies DE
    J. Allergy Clin. Immunol., 2006-09-08;118(4):858-65.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Immunoprecipitation
  23. Level of expression of IL-13R alpha 2 impacts receptor distribution and IL-13 signaling.
    Authors: Daines MO, Tabata Y, Walker BA, Chen W, Warrier MR, Basu S, Hershey GK
    J. Immunol., 2006-06-15;176(12):7495-501.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  24. Protection of human conjunctival fibroblasts from NO-induced apoptosis by interleukin-4 or interleukin-13.
    Authors: Fujitsu Y, Fukuda K, Kimura K, Seki K, Kumagai N, Nishida T
    Invest. Ophthalmol. Vis. Sci., 2005-03-01;46(3):797-802.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  25. Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo.
    Authors: Trieu Y, Wen XY, Skinnider BF, Bray MR, Li Z, Claudio JO, Masih-Khan E, Zhu YX, Trudel S, McCart JA, Mak TW, Stewart AK
    Cancer Res., 2004-05-01;64(9):3271-5.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: Immunoprecipitation

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs

Isotype Controls

Reconstitution Buffers

Secondary Antibodies

Goat IgG (H+L) Antibody

WB,ELISA

Reviews for Human IL-13 R alpha 2 Antibody

There are currently no reviews for this product. Be the first to review Human IL-13 R alpha 2 Antibody and earn rewards!

Have you used Human IL-13 R alpha 2 Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review